Company News: GlaxoSmithKline, Eli Lilly

Share this article:

GlaxoSmithKline has announced plans to commit $1 million of its Cevarix cervical cancer vaccine to the Pink Ribbon Red Ribbon partnership over the next five years, which will afford more than 10,000 girls and women to have access to vaccination. The company has also pledged $50,000 to support the overall program's operations. The Pink Ribbon Red Ribbon partnership is an initiative led by the George W. Bush Institute, the President's Emergency Plan for AIDS Relief (PEPFAR), Susan G. Komen for the Cure and the Joint United Nations Program on HIV/AIDS (UNAIDS). Over time, this program will look to expand the availability of prevention, screening and treatment programs for cervical and breast cancer in developing countries, according to a release.

Eli Lilly and Co. has announced plans to dedicate $30 million over the next five years to a program called Lilly NCD Partnership, which will focus on finding better ways to fight diabetes in developing nations. The company also will also sponsor a conference in Washington, D.C., on Wednesday to discuss the treatment of non-communicable diseases, such as diabetes. This decision comes in conjunction with the United Nations' global efforts in bringing attention to fight the rise in diabetes, cancer and other non-communicable diseases in developing nations. For this initiative, Lilly will target its spending in Brazil, India, Mexico and South Africa, where the rates of diabetes currently run from about 5% to 10% of the populations.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.